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Abstract
Many advances have been made in the diagnosis and management of heart failure (HF) in recent
years. Cardiac biomarkers are an essential tool for clinicians: point of care B-Type Natriuretic
Peptide (BNP) and its N-terminal counterpart (NT-proBNP) levels help distinguish cardiac from
non-cardiac causes of dyspnea and are also useful in the prognosis and monitoring of the efficacy
of therapy. One of the major limitations of HF biomarkers is in obese patients where the
relationship between BNP and NT-proBNP levels and myocardial stiffness is complex. Recent
data suggest an inverse relationship between BNP and NT-proBNP levels and body mass index.
Given the ever-increasing prevalence of obesity world-wide, it is important to understand the
benefits and limitations of HF biomarkers in this population. This review will explore the biology,
physiology, and pathophysiology of these peptides and the cardiac endocrine paradox in HF. We
also examine the clinical evidence, mechanisms, and plausible biological explanations for the
discord between BNP levels and HF in obese patients.
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Introduction
The obesity pandemic is a leading cause of morbidity and mortality across the world. In the
United States an estimated one-third of Americans are obese, presenting a significant and
growing public health concern [1]. Obesity is a risk factor for systemic hypertension,
hyperlipidemia, diabetes mellitus, and left ventricular hypertrophy. These conditions, in
turn, are associated with an increased prevalence of chronic heart failure (CHF), which
results in the death of about half of the patient population within 5 years of diagnosis [2,3].
An estimated 5.1 million people are living with CHF in the United States, costing about $32
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billion in health care costs and loss of productivity [3]. CHF is a progressive disease whose
management requires close monitoring of the patient’s clinical status.
Obese patients, however, present unique challenges in the diagnosis of CHF, particularly in
the emergency department (ED) settings [4–6]. Obesity may mask signs of edema and
auscultation may be difficult during physical examination [6]. Obese patients may also
present dyspnea and orthopnea, characteristic symptoms of CHF, from deconditioning and
abdominal size, respectively. In addition, body habitus also diminishes the image quality of
echocardiograms and chest radiographs [7,8]. Consequently, the use of molecular
biomarkers to aid in the diagnosis and management of CHF would be particularly valuable
in obese patients. The circulating biomarkers for myocardial stiffness, the brain natriuretic
peptides BNP and NT-proBNP, are used to establish or exclude the diagnosis of CHF in
patients with acute dyspnea in the ED. Higher natriuretic peptide levels increase the
likelihood that etiology of dyspnea is due to HF [9]. However, the use of these markers is
compromised in obese patients as their levels tend to be lower. In this review, we will
discuss the biochemistry, physiology, and clinical use of BNP and NT-proBNP in obese
patients with CHF. Finally, we will explore the biological basis underlying the inverse
relationship between BNP and NT-proBNP levels and obesity.
B-Type Natriuretic Peptide
BNP belongs to a family of natriuretic peptides, which includes atrial natriuretic peptide
(ANP) and C-type natriuretic peptide (CNP), with the latter mainly secreted by vascular
endothelium. ANP and BNP are cardiac natriuretic peptides secreted by myocytes, with
BNP mainly secreted by atrial myocytes in the normal heart [10,11]. Ventricular BNP
secretion increases drastically in CHF, indicative of greater ventricular stress and serious
cardiac dysfunction [12–14]. The precursor of human BNP, preproBNP, is 134 amino acids
(aa) in length and is a theoretically deduced form which does not exist as a separate entity
[14]. PreproBNP is processed to 108 aa proBNP by the cleavage of N-terminal 26 aa signal
peptide. The proBNP is cleaved by serine endoproteases corin and furin into an inactive 76
aa N-terminal peptide, NT-proBNP and a C-terminal 32 aa long active hormone, BNP [15].
BNP contains a ring structure formed by a disulfide bond between the cysteine residues
Cys10 and Cys26, which is essential for receptor binding and biological activity [16]. In
addition to NT-proBNP and BNP, unprocessed proBNP also circulates in the plasma, whose
levels may be more compared with the cleavage products in severe HF [14].
Cardiac natriuretic peptides are released from the heart under physiological conditions and
are involved in cardiovascular homeostasis [17–19]. This is achieved, in part, by integrating
the function of renal system. Natriuretic peptides induce dilation of afferent and constriction
of efferent renal arterioles, resulting in increased glomerular filtration and enhanced
natriuresis and diuresis [20,21]. In addition, these peptides decrease cardiac preload by
shifting intravascular fluid into the interstitial space [22]. Natriuretic peptides suppress
renin-angiotensin-aldosterone system (RAAS) and the release of renin from the kidney and
aldosterone from the adrenal gland, which enhances natriuresis and the reduction of
extracellular volume [23–25].
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Natriuretic peptides suppress sympathetic nerve activity in the peripheral vasculature,
perhaps by lowering the activation threshold of baroreceptors, by suppressing catecholamine
release from the nerve endings, and by the inhibition of the sympathetic outflow [21,26–28].
Because these peptides lower the activation threshold of vagal afferents, reflex tachycardia
and vasoconstriction that follow reduction in the preload are suppressed, effecting a
sustained decrease in mean arterial pressure. Relaxation of smooth muscle cells and
suppression of RAAS induced by the natriuretic peptides decrease systemic and peripheral
vascular resistance [29]. Furthermore, natriuretic peptides may function as endogenous
inhibitors of cardiac hypertrophy and fibrosis [30,31].
Natriuretic peptide secretion increases in proportion to the severity of the left ventricular
dysfunction, suggesting that end-diastolic wall stress is the main regulatory mechanism
[32,33]. However, increased peptide levels are also found in patients with renal failure or
pulmonary hypertension and may increase in arterial hypertension or liver cirrhosis [34].
Increased BNP levels were reported in patients with acute coronary syndrome or during
exercise-induced ischemia, in the absence of significant ventricular dilation [35–38]. Plasma
ANP levels were chronically elevated following cardiac transplantation even after the return
of cardiac function and normalization of RAAS [39]. These observations suggest an active
involvement of the neurohormonal and immune systems in the regulation of the natriuretic
peptide levels, which is supported by in vitro and animal model studies. For example,
angiotensin II and endothelin induced BNP synthesis in rat cardiomyocytes as well as in
anaesthetized rats [40]. Similarly, plasma natriuretic peptide levels were increased in rat
experimental autoimmune myocarditis [41]. In addition, proinflammatory cytokines tumor
necrosis factor-α, interleukin-1β, and interleukin-6 induce BNP synthesis in cardiomyocytes
[42,43]. These data suggest a complex interaction among mechanical, neurohormonal, and
immunological components in the regulation of cardiac endocrine response involving
natriuretic peptide synthesis/secretion.
Compared with the healthy subjects, a progressive increase in median BNP levels of up to
57-fold and median NT-proBNP levels of up to 107-fold was observed in patients with HF
(discussed later) in NYHA class IV/stage D [44]. Despite the direct diuretic and natriuretic
effects of natriuretic peptides, congestion, sodium retention, and edema are the hallmarks of
CHF [14]. This cardiac endocrine paradox suggests a blunted biological effect of the
peptides, mainly on natriuresis, which can be attributed to three main mechanisms [38, 45].
First, the blunted effect may result from impaired post-translational processing of
biosynthetic precursors of BNP [14,46–50]. Consistent with this, Dong et al. [49] reported a
significant decrease in the plasma levels of corin involved in proBNP processing, in CHF
patients compared with the healthy controls, with the decrease in the enzyme level
correlated with the severity of the disease. Increased levels of proBNP, with reduced
efficacy in the activation of NPR-A receptor (discussed later) compared with BNP, can
impair natriuresis [51]. In addition, the resistance of proBNP to degradation may result in
the increased proBNP:BNP ratio observed in CHF patients, contributing to peripheral
resistance to the biological activation of natriuretic peptides. Second, altered expression of
natriuretic peptide receptors might also contribute to resistance to the biological effect of the
peptides in CHF [52–55]. Another potential mechanism of resistance includes homologous
desensitization of the NPR-A receptor [38], protein kinase C-dependent heterologous
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desensitization of NPR-A by vasoconstrictive hormones [56], increased activity of
phosphodiesterases that hydrolyze cGMP [57,58] and the refractory nature of NPR-A to
natriuretic peptide stimulation [59].
Clinical Use of BNP and NT-proBNP
In the 1990s, the advent of assays for measuring serum levels of BNP allowed researchers to
investigate the use of BNP as a clinical biomarker for CHF [60]. A large number of studies
showed strong evidence for the use of BNP levels to aid in the diagnosis of HF in patients
who present with acute dyspnea. In 2005, Wang et al. conducted a meta-analysis to evaluate
the diagnostic value of circulating BNP levels [61]. They found that, across a pool of eleven
studies, high BNP levels (>250 pg/mL) increased the chances of CHF by 2–4.5 times.
Additionally, moderate to low BNP levels (<250 pg/mL) were associated with a 90%
decrease in the incidence of CHF [60,61]. The validity of using BNP levels to diagnose HF
in the emergent setting was also supported by the large-scale multi-center Breathing Not
Properly (BNP) Study, which evaluated 1586 patients who presented with acute dyspnea [4].
This study found that patients diagnosed with CHF had significantly higher BNP levels
(mean BNP 675 pg/mL) than patients with base-line left ventricular dysfunction but other
causes of dyspnea (mean BNP 346 pg/mL) or no left ventricular dysfunction or HF (mean
BNP 110 pg/mL). Based on this, Maisel et al. [4] established the widely used standard of
BNP level >100 pg/mL as a cutoff for CHF as the etiology for acute dyspnea in the
emergent setting (sensitivity 90% and specificity 76%) (Table 1).
Using a design similar to the above mentioned BNP study, in the N-Terminal Pro-BNP
Investigation of Dyspnea in the Emergency Department (PRIDE) study Januzzi et al. [62]
investigated the utility of NT-proBNP for the diagnosis of CHF in 600 dyspnea patients, a
cohort with a final diagnosis of 35% acute CHF. An age-stratified analysis determined a
rule-in cut point of 450 pg/mL for patients <50 years (sensitivity 93% and specificity 95%)
and 900 pg/mL for patients ≥ 50 years (sensitivity 91% and specificity 80%). More recently,
Hildebrandt et al. [63] further refined age-based cut points for NT-proBNP levels after
analyzing data of 5508 primary care patients from 10 studies in several countries. NT-
proBNP values of 50 ng/L (sensitivity 99.2%, specificity 57.2%, and negative predictive
value 99.7%), 75 ng/L (sensitivity 95.9%, specificity 51.0%, and negative predictive value
96.8%), and 250 ng/L (sensitivity 87.9%, specificity 53.7%, and negative predictive value
92.4%) for <50, 50–75, and >75 years, respectively, were superior to a single cut point to
rule out HF. Emphasizing the importance of age stratification in improving diagnostic
sensitivity, the data from the International Collaborative of NT-proBNP (ICON) study
identified rule in cut points for acute HF of 450, 900, and 1800 pg/mL for patients aged <50,
50–75, and >75 years, respectively (90% sensitivity and 84% specificity) [64] (Table 1).
However, an age-independent cut point of 300 pg/mL of NT-proBNP was sufficient to rule
out acute HF, demonstrating 99, 60, and 98% of sensitivity, specificity, and negative
predictive value, respectively.
Both the BNP and PRIDE studies show that BNP and NT-proBNP levels in combination
with clinical judgment are superior to natriuretic factors levels or clinical judgment alone,
indicating the importance of integrating the testing of these peptides with clinical assessment
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for the diagnosis of CHF in patients who present with dyspnea in the emergency department
[62,65]. Supporting this notion, in a prospective study of 3870 older men NT-proBNP
improved prediction of CHF above routine conventional risk factors and the Health ABC
Heart Failure Score in all men and in men with and without established CVD (P<0.0001 for
improvement in c-statistics [66]. However, the consensus is that natriuretic peptide level is
not a stand-alone test and as a quantitative marker, it is better used as a continuous variable
in the treatment of CHF [9]. While left ventricular ejection fraction <40% is considered a
threshold for causing chronic systolic HF, 40–50% of HF patients have normal ejection
fractions without an apparent systolic dysfunction [67–69]. HF patients with ejection
fractions >45 or 50% are referred to as having “HF with preserved systolic function”
(HFPSF) or “nonsystolic HF” [70,71]. BNP levels also help distinguish patients with HFPSF
from those without HF, although a measurement of LV function is necessary distinguish
between HFPSF from systolic HF [70]. Similarly, increased NT-proBNP levels indicate
increased risk for both systolic HR and HFPSF [72].
In addition to its utility in CHF diagnosis, several studies have established that circulating
BNP levels are a powerful prognostic indicator in HF. Anand et al. analyzed data from the
Valsartan Heart Failure Trial (Val-HeFT) of ~4300 patients to evaluate the predictive power
of BNP levels [73]. Their data revealed that levels above 97 pg/mL are associated with twice
the risk of morbidity and mortality. Additionally, Tsutamoto et al. found, in a prospective
study of 290 patients with asymptomatic or minimally symptomatic left ventricular
dysfunction, that plasma BNP levels >56 pg/mL were an independent predictor for mortality
[74].
Owing to its strong diagnostic and prognostic power, there has been great interest in using
BNP to guide individual patient management. In the aforementioned Val-HeFT study,
patients with the largest increase in BNP from the pre-treatment baseline had the highest
mortality, whereas those with greatest decline the lowest mortality [73,75]. Similarly, a
study by Jourdain et al. examined the relative effectiveness of established dosing guidelines
against dosing based on changes in BNP levels for angiotensin-converting enzyme
inhibitors, beta-blockers, and diuretics in the treatment of CHF [76]. Over a 15 month
period, the group that received BNP-guided dosing had significantly reduced risk of CHF-
related death or hospital stay for CHF (24% vs. 52%, P<0.001). These promising early
reports invite further study as they suggest an exciting and innovative way to personalize
CHF treatment approaches to individual patients.
The Relationship Between BMI and BNP
There are many variables that affect BNP levels in a patient, including gender and age [77],
hypertension [78], renal disease [79], and atrial fibrillation [80]. The increase in natriuretic
peptide levels with age likely reflects age-related decreases in left ventricular compliance
[81] and glomerular filtration rate [82]. Recently, researchers have demonstrated a consistent
inverse relationship between obesity (defined as having a BMI of 30 or greater) and
circulating BNP levels. Wang et al. [83] were the first to describe the inverse relationship
between obesity and BNP levels in a study of 3389 subjects from the original Framingham
Heart Study offspring cohort, none of whom had HF. Multivariable regression analysis was
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adjusted for echocardiographic variables such as left ventricular mass and left atrial size.
The mean plasma BNP levels were 21.4, 15.5, and 12.7 pg/mL in lean (BMI<25),
overweight (BMI of 25 to 29.9), and obese (BMI greater than or equal to 30), respectively.
One important limitation of this study was its cross-sectional design and it was not possible
to determine whether the low BNP levels preceded or followed the development of obesity.
Examination of a large population-based cohort of the Dallas Heart Study confirmed the
report of Wang et al. [83], demonstrating the inverse relationship among BMI, BNP, and
NT-proBNP levels. This study included 2707 patients, who were randomly selected
residents of Dallas County, aged 30 to 65 [84]. The association between obesity and low
BNP values (<4 ng/L), or low NT-proBNP (lowest sex-specific quartile; <7.6 ng/L for men
and <20.4 ng/L for women) evaluated with multivariable regression models adjusted for age,
gender, ethnicity, left ventricular mass, hypertension, and end diastolic volume showed that
higher BMI values were associated with lower BNP and NT-proBNP levels (P<0.001).
However, upon replacement of BMI with direct dual energy x-ray absorptiometry-derived
lean and fat mass, higher lean mass correlated more closely with low BNP and NT-proBNP
levels. Decreased NT-proBNP levels were also observed in obese patients with stable as
well as acute CHF [85,86]. In contrast, after adjusting for age and sex in a multivariate
analysis of participating residents of Olmsted County, MN, BMI had no significant effect on
NT-proBNP levels in an apparently healthy cohort of 746 subjects [87].
The Suita study examined 1759 subjects from urban areas in Japan, without heart disease, to
determine if the inverse relationship between BMI and BNP existed among a population
with lower BMIs versus those in Western countries, where more studies on this subject have
been done [88]. The subjects ranged from 38 to 95 years of age with a mean BMI of 22.8.
Multivariable regression analysis, adjusting for age, pulse rate, serum creatinine, systolic
blood pressure, and left ventricular hypertrophy, showed an inverse relationship between
BMI and BNP levels in both sexes (P<0.01). The Suita study is particularly interesting
because it demonstrated that the inverse relationship between BMI and BNP remains valid
in a cross-cultural setting. This will rule out the involvement of confounding dietary or
lifestyle factors in regulating BNP levels.
The biological link between obesity and BNP
A number of hypotheses have been put forth in an attempt to explain the inverse relationship
between obesity and circulating BNP levels. However, to date there has been no conclusive
evidence in favor of any particular hypothesis.
Kidneys
Renal function, more specifically glomerular filtration rate, has been reported to depress
BNP levels in obese CHF patients [89] because obesity is associated with substantially
higher glomerular filtration rates [90]. This suggests that obese patients may have depressed
circulating BNP levels simply because they are clearing these molecules more effectively.
Given the short half-life of BNP (~23 minutes), this explanation is plausible. However the
Suita study argues against this theory as their multivariable regression analysis was adjusted
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for serum creatinine among other variables, and still found the inverse relationship between
BMI and BNP [88].
Adipose Tissue
Adipose tissue expansion is one of the defining characteristics of obesity. Adipocytes are
known to highly express natriuretic peptide clearance receptors-C (NPR-C), causing some to
speculate that this is the basis for low serum BNP levels associated with obesity [91,92].
However, the Dallas Heart Study showed that obesity is also linked with lower levels of NT-
proBNP, which is not cleared by the NPR-C [84]. Additionally, the Dallas Heart Study
found that BNP and NT-proBNP levels were more closely correlated with lean mass than
with BMI, suggesting that adipose tissue itself may not be the driving force in this
relationship. The authors postulate that a substance produced in the lean mass either
suppresses the synthesis or release of the natriuretic peptides or an androgen coordinately
regulates natriuretic peptide synthesis and body composition. Alternatively, the fat mass
measured by dual energy x-ray absorptiometry in this study might mostly consist of
subcutaneous adipose tissue [93]. In a study of 1873 community-based individuals, Cheng et
al. [94] found an inverse relationship between NT-proBNP levels and visceral adipose mass,
which was attenuated after adjustment for HOMA-IR (homeostasis model assessment of
insulin resistance), indicating a role for hyperinsulinemia in lower natriuretic peptide levels
in obesity. These data are consistent with the reports that hyperinsulinemia attenuates
natriuretic peptide secretion and activity [95,96]. However, acute insulin administration has
either no significant effect [97] or increased [98] natriuretic peptide levels, indicating
perhaps the differential physiological effects of acute vs chronic hyperinsulinemia on
natriuretic peptide levels.
Interestingly, several investigators have postulated a 'bidirectional relationship' between
BNP and adiposity because BNP has been shown to cause lipolysis in adipocytes (Figure 1).
They point out that low levels of BNP could lead to less lipolysis and thus promote obesity
[92,93]. Supporting this hypothesis, Cabiati et al. [99] recently reported significantly lower
levels of BNP and a reduction of ANP and CNP mRNA levels in the hearts of obese
compared with the control rats. Furthermore, BNP induced lipolysis may underlie the
wasting (cardiac cachexia) seen in patients with severe HF [92]. Natriuretic peptides exert
their biological effects via stimulation of NPR-A (GC-A/NPR-1) and NPR-B (GC-B/
NPR-2), two receptors which act as membrane-bound guanylyl cyclases [100]. ANP and
BNP preferentially bind to NPR-A, where CNP is a physiological ligand for NPR-B [101].
Stimulation of these receptors generates cyclic guanosine monophosphate (cGMP) and
subsequent activation of cGMP-dependent protein kinase 1 (cGK1), which constitute the
nitric oxide signal transduction pathway [102].
Using three types of genetically engineered mouse models ─BNP transgenic, cGK
transgenic and NPR-A heterozygous knockout mice─ Miyashita et al. [102] demonstrated
that increased natriuretic peptide levels prevent accumulation of abdominal fat in mice on
high fat diet, by promoting mitochondrial biogenesis in skeletal muscle, through increased
expression of peroxisome proliferator-activated receptor (PPAR)-γ coactivator (PGC)-1α
and PPARδ, via the activation of cGMP/cGK1 signaling cascade (Figure 1). In addition,
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BNP transgenic mice were protected against diet-induced insulin resistance. Cardiac
natriuretic peptides also induced mitochondrial biogenesis by increasing the expression of
PGC-1α and PPARδ in C2C12 myotubes. More importantly, high fat diet decreased the
expression of NPR-A and NPR-B and increased the expression of NPR-C in skeletal muscle,
brown and white adipose tissue. A low NPR-A:NPR-C ratio could decrease natriuretic
peptide induced cGMP/cGK1 signaling pathways as well as natriuretic peptide levels within
the tissue [103,104].
In tune with the above data, natriuretic peptides activated PGC-1α, induced
mitochondriogenesis, and increased respiration in human adipocytes [105]. Additionally,
infusion of BNP into mice significantly increased the expression of uncoupling protein 1, a
mediator of thermogenic energy expenditure and PGC-1α in adipose tissue, suggesting a
role in regulation of obesity. In this context, it is of interest to note that calorie restriction
promotes muscle mitochondrial biogenesis in rodents [106] as well as humans [107] by
increasing the levels of nitric oxide, the upstream activator of cGMP/cGK1 pathway.
Emerging evidence suggests that natriuretic peptides control lipolysis and lipid mobilization
in physiological and pathological conditions [108]. Further supporting the protective effect
of natriuretic peptides against obesity, Sengenés et al. [92] reported that cardiac natriuretic
peptides induce strong lipolysis in isolated human fat cells by producing cGMP via the
NPR-A receptor. Activation of cGMP/cGK1 pathway increases the phosphorylation of
perilipin-A and hormone-sensitive lipase, a rate-limiting enzyme in lipolysis [109].
Perilipin-A phosphorylation results in the physical alteration of the surface of the lipid
droplet, facilitating the binding of the hormone-sensitive lipase and hydrolysis of
triglycerides into free fatty acids and glycerol.
Congruent with this data, a meta-analysis of 49279 subjects from seven case-controlled
studies showed that BNP promoter T-381C polymorphism (rs198389), associated with
higher BNP levels, has modest protective effect against type 2 diabetes [110]. However, this
polymorphism is not associated with a decreased HF risk in large population based-cohort
studies, indicating that increase in BNP levels because of the genetic variation might not be
large enough to cause clinically detectable risk reduction [111,112]. Supporting the role of
natriuretic peptides in adiposity, significant increases in the levels of BNP and NT-proBNP
were observed in obese patients following gastric bypass surgery [113,114]. Similarly,
weight loss as a result of comprehensive lifestyle changes in patients with coronary heart
disease and coronary heart disease risk factors and/or diabetes mellitus decreased insulin and
increased BNP levels [115], suggesting that loss of natriuretic peptide clearance pathways as
well as hyperinsulinemia regulate natriuretic peptide levels.
Validity of BNP as a marker for CHF in Obese Patients
Because obese subjects have BNP levels below the traditional cutoff used to diagnose CHF,
lower thresholds should be used to diagnose HF in this patient population [6]. Based on the
established clinical threshold of 100 pg/mL, BNP testing yielded false negative results in
20% of obese HF patients [6,116]. Hence, a cut point of BNP ≤ 54 pg/mL is recommended
for ruling out CHF in severely obese patients (BMI ≥ 35) (Table 1) [6]. It is also suggested
that a higher BNP cut point of ≥170 pg/mL in lean patients increases specificity. In contrast
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to BNP cut points, relatively lower concentrations NT-proBNP in overweight and obese
patients with acute dyspnea retain their diagnostic and prognostic capacity [117]. A cut point
of 300 ng/L NT-proBNP had highly significant negative likelihood ratio of 0.02, 0.03, and
0.08 for BMI of <25.0, 25.0–29.9, and ≥30.0, respectively, ruling out acute HF. Also, a NT-
proBNP cut point of >986 ng/L remained strongly prognostic across all 3 BMI groups.
Conclusions
HF has become the most common cardiovascular diagnosis in hospitalized patients and, at
the same time, the proportion of HF patients with significant obesity has increased
dramatically due to the increase in obesity in the general population. For this reason, more
precise understanding on the inter-relationship between BMI and BNP measurements is of
critical importance and will facilitate more accurate diagnosis of HF in obese patients. In
this review, we have illustrated new knowledge on important relationships that exist
between natriuretic peptides and lipid metabolism as well as the regulation of natriuretic
peptide secretion and activity in normal body weight and obesity. Further basic and
translational research offers the possibility of formulating new therapeutic strategies for
treatment of vascular and metabolic diseases in general and CHF in particular.
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• The biology, physiology, and pathophysiology of BNP and NT-proBNP
peptides and cardiac endocrine paradox in heart failure was examined.
• The diagnostic and prognostic value of BNP and NT-proBNP levels in heart
failure was enumerated.
• The discord between BNP levels and heart failure in obese patients was
discussed, with validation of new cut points.
• Plausible mechanisms and biological explanations for the discord between BNP
levels and heart failure in obese patients were proposed.
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A proposed bidirectional relationship between BNP and obesity. Under normal conditions,
BNP acting through the NPR-A receptor induces cGMP signaling which promotes lipolysis
in adipose tissue and mitochondrial biogenesis and fat oxidation in skeletal muscle. These
physiological actions provide protection against obesity and insulin resistance. Contrast to
this, in obese patients and people with insulin resistance BNP secretion and activity are
decreased and NPR-A:NPR-C ratio is altered, impairing NPR-A/cGMP/cGK1 signaling, as
also reported during high fat feeding and/or physical inactivity [adapted from Moro and
Smith, 104].
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